Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers"

• Published in: Clinical pharmacology and therapeutics Vol. 95; no. 3; p. 252
• Main Authors: Markova, S M, Schwartz, J B, Kroetz, D L
• Format: Journal Article
• Language: English
• Published: United States 01.03.2014
• Subjects: Aryl Hydrocarbon Hydroxylases - genetics; Chemical and Drug Induced Liver Injury - etiology; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary - drug therapy; Male; Sulfonamides - adverse effects
• ISSN: 1532-6535
• DOI: 10.1038/clpt.2013.239